In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
-
CORPORATE - 04-10-2019
Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY
read more -
CORPORATE - 05-11-2018
First Annual International Symposium for the Global Eradication of Rh Disease ends a year of celebrations
The event, supported by Kedrion among others, was held on November 1st at Columbia University in NY
read more -
CORPORATE - 05-09-2018
Kedrion joins Rhesus Solution Initiative (RSI) symposium in Lagos
Nigeria to advocate for Rh Disease universal eradication
read more -
CORPORATE - 16-02-2018
Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017
The prize is awarded to the companies that made the best use of the capital markets
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 